7,561.90

+20.50

+0.27%

51,762.58

-221.40

-0.43%

25,327.38

+163.01

+0.65%

2,822.11

+16.23

+0.58%

4.9460

+0.0520

+1.06%

20.74

-0.41

-1.94%

3,934.10

-35.50

-0.89%

77,449.74

+498.27

+0.65%

Crude Oil Dec 26

96.25

-0.21

-0.22%

US Private Equity

10,836.30

-14.33

-0.13%

NasdaqGM - Nasdaq Real Time Price USD

Rapport Therapeutics, Inc. (RAPP)

25.47 +0.34 (+1.35%)

As of 2:56:59 PM EST. Market Open.

Trade RAPP on Coinbase

Loading Chart for RAPP

Chart Range Bar

Interval:

In partnership with ChartIQ

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement

Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement

Rapport Therapeutics Prices Stock, Convertible Notes Offerings; Private Placement; Shares Fall

Rapport Therapeutics Prices Stock, Convertible Notes Offerings; Private Placement; Shares Fall

Rapport Therapeutics stock tumbles on $350M capital raise

Rapport Therapeutics stock tumbles on $350M capital raise

Rapport Therapeutics Sinks 22% on Discounted $350 Million Stock and Convertible Note Raise

Rapport Therapeutics Sinks 22% on Discounted $350 Million Stock and Convertible Note Raise

Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement

Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement

Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement

Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement

Rapport Therapeutics (RAPP) Could Be 62% Below Fair Value Following Phase 2 Mania Data

Rapport Therapeutics (RAPP) Could Be 62% Below Fair Value Following Phase 2 Mania Data

Rapport Therapeutics (RAPP) Stock Gets Fair Value Boost After RAP 219 Bipolar Mania Data

Rapport Therapeutics (RAPP) Stock Gets Fair Value Boost After RAP 219 Bipolar Mania Data

Why Rapport Therapeutics (RAPP) Is Up 5.8% And What's Next

Why Rapport Therapeutics (RAPP) Is Up 5.8% And What's Next

Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Rises

Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Rises

Mobilize your Website

View Site in Mobile | Classic

Share by: